AAAAAA
Results:
1-9
|
Results: 9
Authors:
Goelen, G
Rigo, A
Fontaine, C
Wanrooij, B
De Greve, J
Citation: G. Goelen et al., Moral issues in day-to-day palliative medicine and their relevance for theeducation of European general practitioners, J CANCER ED, 16(1), 2001, pp. 12-14
Authors:
Neyns, B
Vermeij, J
Teugels, E
De Rijcke, M
Hermonat, P
De Greve, J
Citation: B. Neyns et al., Characterization of permanent cell lines that contain the AAV2 rep-cap genes on an Epstein-Barr-virus-based episomal plasmid, INTERVIROLO, 44(4), 2001, pp. 255-263
Authors:
Hemonat, PL
Santin, AD
De Greve, J
De Rijcke, M
Bishop, BM
Han, L
Mane, M
Kokorina, N
Citation: Pl. Hemonat et al., Chromosomal latency and expression at map unit 96 of a wild-type plus adeno-associated virus (AAV)/Neo vector and identification of p81, a new AAV transcriptional promoter, J HUMAN VIR, 2(6), 1999, pp. 359-368
Authors:
Goelen, G
Rigo, A
Bonduelle, M
De Greve, J
Citation: G. Goelen et al., Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing, J CL ONCOL, 17(5), 1999, pp. 1595-1600
Authors:
Zeinoun, Z
Teugels, E
De Bleser, PJ
Neyns, B
Geerts, A
De Greve, J
Citation: Z. Zeinoun et al., Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines, ANTICANC R, 19(1A), 1999, pp. 413-420
Authors:
Cocquyt, V
Kline, WF
Gertz, BJ
Van Belle, SJP
Holland, SD
DeSmet, M
Quan, H
Vyas, KP
Zhang, KYE
De Greve, J
Porras, AG
Citation: V. Cocquyt et al., Pharmacokinetics of intravenous alendronate, J CLIN PHAR, 39(4), 1999, pp. 385-393
Authors:
Goelen, G
Teugels, E
Bonduelle, M
Neyns, B
De Greve, J
Citation: G. Goelen et al., High frequency of BRCA1/2 germline mutations in 42 Belgian families with asmall number of symptomatic subjects, J MED GENET, 36(4), 1999, pp. 304-308
Authors:
Neyns, B
Teugels, E
Bourgain, C
Birrer, M
De Greve, J
Citation: B. Neyns et al., Alteration of jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells, INT J CANC, 82(5), 1999, pp. 687-693
Authors:
Marchand, M
van Baren, N
Weynants, P
Brichard, V
Dreno, B
Tessier, MH
Rankin, E
Parmiani, G
Arienti, F
Humblet, Y
Bourlond, A
Vanwijck, R
Lienard, D
Beauduin, M
Dietrich, PY
Russo, V
Kerger, J
Masucci, G
Jager, E
De Greve, J
Atzpodien, J
Brasseur, F
Coulie, PG
Van der Bruggen, P
Boon, T
Citation: M. Marchand et al., Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, INT J CANC, 80(2), 1999, pp. 219-230
Risultati:
1-9
|